DCR = PR + CR + SD (stable disease)
• Complete Response (CR): The complete disappearance of all measurable tumors.
• Partial Response (PR): At least a 30% reduction in tumor size.
• Stable Disease (SD): Changes fall anywhere between a 29% decrease and a 19% increase.
• Progressive Disease (PD): At least a 20% increase in tumor size (or the appearance of new lesions)
Highlights of revised RECIST 1.1: Major changes include: Number of lesions to be assessed: based on evidence from numerous trial databases merged into a data warehouse for analysis purposes, the number of lesions required to assess tumour burden for response determination has been reduced from a maximum of 10 to a maximum of five total (and from five to two per organ, maximum). Assessment of pathological lymph nodes is now incorporated: nodes with a short axis of P15 mm are considered measurable and assessable as target lesions. The short axis measurement should be included in the sum of lesions in calculation of tumour response. Nodes that shrink to <10 mm short axis are considered normal. Confirmation of response is required for trials with response primary endpoint but is no longer required in randomised studies since the control arm serves as appropriate means of interpretation of data. Disease progression is clarified in several aspects: in addition to the previous definition of progression in target disease of 20% increase in sum, a 5 mm absolute increase is now required as well to guard against over calling PD when the total sum is very small.
https://dctd.cancer.gov/research/ctep-trials/...es-v11.pdf
• Complete Response (CR): The complete disappearance of all measurable tumors.
• Partial Response (PR): At least a 30% reduction in tumor size.
• Stable Disease (SD): Changes fall anywhere between a 29% decrease and a 19% increase.
• Progressive Disease (PD): At least a 20% increase in tumor size (or the appearance of new lesions)
Highlights of revised RECIST 1.1: Major changes include: Number of lesions to be assessed: based on evidence from numerous trial databases merged into a data warehouse for analysis purposes, the number of lesions required to assess tumour burden for response determination has been reduced from a maximum of 10 to a maximum of five total (and from five to two per organ, maximum). Assessment of pathological lymph nodes is now incorporated: nodes with a short axis of P15 mm are considered measurable and assessable as target lesions. The short axis measurement should be included in the sum of lesions in calculation of tumour response. Nodes that shrink to <10 mm short axis are considered normal. Confirmation of response is required for trials with response primary endpoint but is no longer required in randomised studies since the control arm serves as appropriate means of interpretation of data. Disease progression is clarified in several aspects: in addition to the previous definition of progression in target disease of 20% increase in sum, a 5 mm absolute increase is now required as well to guard against over calling PD when the total sum is very small.
https://dctd.cancer.gov/research/ctep-trials/...es-v11.pdf
5
